Subtype
Malignant Pharyngeal Neoplasm
CI-CAN-00003219Explore in graph →
411 active trials1 approved drugs2 evidence items
- NCIt
- C7545
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003219Explore in graph →
Clinical trials
1,255 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (112)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07290621 | Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer | recruiting | Phase 2 | 30 | University of ChicagoOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05962242 | HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma(HN001) | recruiting | Phase 2 | 90 | University of VirginiaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07388758 | Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07388836 | Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 198 | Fujian Cancer HospitalOTHER_GOV | 0 | Feb 5, 2026 | clinicaltrials |
| NCT07332247 | PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC | recruiting | Phase 2 | 94 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07385079 | Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 412 | Sun Yat-sen UniversityOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT05894083 | A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) | recruiting | Phase 2 | 150 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | recruiting | Phase 1 / Phase 2 | 72 | Theravectys S.A.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT02065362 | TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376603 | IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features | recruiting | — | 169 | Qiaojuan GuoOTHER_GOV | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03210103 | Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer(ORATOR2) | active not recruiting | N/A | 61 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Jan 28, 2026 | clinicaltrials |
| NCT07373990 | Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 418 | Sun Yat-sen UniversityOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT03468218 | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer | active not recruiting | Phase 2 | 36 | Emory UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07101744 | Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial | recruiting | Phase 2 | 41 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03891953 | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | active not recruiting | Phase 1 | 98 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 21, 2026 | clinicaltrials |
| NCT05312710 | Safety and Efficacy of APG-157 in Head and Neck Cancer | active not recruiting | Phase 2 | 24 | Aveta Biomics, Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07343271 | Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx(DECT-CEco) | recruiting | — | 30 | University Hospital, Strasbourg, FranceOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07340515 | Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial | recruiting | Phase 3 | 300 | Man HuOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07328854 | 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma | recruiting | Phase 3 | 346 | Ming-Yuan ChenOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07331428 | MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC | not yet recruiting | Phase 2 | 25 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2026 | clinicaltrials |
| NCT03215719 | Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma | recruiting | Phase 2 | 120 | NYU Langone HealthOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT04124198 | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma(QoLATI) | active not recruiting | N/A | 138 | Christian von BuchwaldOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05494190 | The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma | recruiting | N/A | 111 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05912582 | Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma | not yet recruiting | — | 60 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03734809 | NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer | active not recruiting | Phase 2 | 43 | Chinese University of Hong KongOTHER | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07303023 | Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC(INCIPT-NPC) | recruiting | Phase 3 | 462 | Fudan UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07248956 | Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma | recruiting | Phase 2 | 116 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07295561 | Salvage Surgery in Recurrent Hypopharyngeal Carcinoma: an Observational Single-institutional Study From 1998 | active not recruiting | — | 100 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05340270 | PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma(NeoTurbo) | active not recruiting | Phase 2 | 150 | Guangxi Medical UniversityOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05793151 | Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy(ENDURE) | recruiting | N/A | 532 | Medical University of South CarolinaOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07277764 | Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)(REDEFINE) | recruiting | Phase 2 | 23 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07188584 | Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer | recruiting | Phase 3 | 166 | Ming-Yuan ChenOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07268690 | Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07267338 | Pembrolizumab + MRGOO3 as Neoadjuvant in NPC | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04908696 | Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC) | recruiting | — | 1,000 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07258979 | A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. | recruiting | Phase 1 / Phase 2 | 202 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07252375 | A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 35 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 26, 2025 | clinicaltrials |
| NCT07154069 | Adaptive Immunotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 802 | Sun Yat-sen UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07248670 | Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC | active not recruiting | Phase 3 | 252 | Chongqing University Cancer HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07248696 | Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial | active not recruiting | N/A | 32 | Chongqing University Cancer HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05333523 | Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.(PRIMO) | recruiting | Phase 3 | 242 | Radboud University Medical CenterOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06839066 | A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy | recruiting | Phase 2 | 70 | Shanghai Henlius BiotechINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07232680 | Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy(IMPRINT) | recruiting | — | 500 | Cheng-En HsiehOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07238569 | Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 516 | Sun Yat-sen UniversityOTHER | 0 | Nov 20, 2025 | clinicaltrials |
| NCT06592716 | Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples? | active not recruiting | — | 200 | Rigshospitalet, DenmarkOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07088861 | Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China | active not recruiting | — | 1,401 | Lirong WuOTHER | 0 | Nov 18, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06088381 | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)(SAVAL) | recruiting | Phase 2 | 61 | University of Maryland, BaltimoreOTHER | 1 | Nov 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 6, 2026source: clinicaltrials